image360

Collaborative Research on Predicting Prostate Cancer Risks

BGI and Maxwell Plus have executed a collaborative research project “A model to predict risk of developing advanced or metastatic prostate cancer using genetic makeup and family history of cancers” in September 2018. Prostate cancer is the second most common type of cancer among males in Western countries, with an estimated 165,000 new cases and 29,500 cancer deaths in 2018 alone. The objective of the project is to understand the genetic makeup of prostate cancer patients and understand how significant the association is between prevalence of prostate, breast, ovarian and colorectal cancers in the families of patients. The risk of the genetic makeup and family history will be combined into a risk model for predicting advanced or metastatic prostate cancer. All samples will be sequenced on the cutting-edge BGI genetic sequencer, MGISEQ-2000, in the BGI Australia laboratory.

About Maxwell Plus

Founded in 2016, Maxwell Plus is a growing Brisbane based medical technology startup rethinking the way we detect and diagnose disease. By combining machine learning with medical imaging the team are working to make cancer diagnosis faster, more affordable and more accurate.